Many factors drive the next-generation sequencing (NGS) market in regulated environments. Only a few years ago, the throughput and price point did not allow for easy transition from existing technologies. The launch of benchtop instruments has significantly reduced the capital equipment costs and simplified the skill sets required for operation, expanding common near-term applications in noninvasive prenatal testing (NIPT),...
![Clinicians devoted to precision oncology are as effective as their computational infrastructure is robust. [Rbhavana/Deposit Photos]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/185.jpeg "Beyond the Sequence")
Whether they are concerned with a mutation of a single gene, or mutations in a combination of two or more genes, today’s oncologists look forward to using genomic information to more precisely target and treat cancer. But as more and more researchers delve into the work of discovering which genetic mutations are associated with specific subtypes of cancer, or...
Lung cancer is one of the most common malignancies and the leading cause of cancer-related fatality. In the United States alone, more than 210,000 new lung cancer cases are diagnosed every year, with more than 170,000 deaths resulting from the disease each year.
Current diagnostic practices for common cancers rely heavily on imaging technologies such as CT scans for lung...
![Increased scrutiny from the Office of Inspector General will force clinical labs to ensure that their practices are sound and their records complete. [WavebreakMediaMicro/Fotolia]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/186.jpeg "Uncle Sam Casts Wary Eye on Clinical Lab Billing")
Washington will keep its eye on clinical laboratories this year—specifically, how much they are billing the federal government for services through Medicare.
The U.S. Department of Health and Human Services, through its Office of Inspector General (OIG), officially threw down the proverbial gauntlet to the labs in its Work Plan for the current federal fiscal year, which ends on September...
The February issue of Clinical OMICs is available now! Check it out by clicking on the link below.
A study, funded by the Movember Foundation and conducted by scientists at The Institute of Cancer Research (ICR) in London, has revealed several genetic mutations that may trigger the development of testicular cancer, in addition to uncovering a gene that may aid tumors in promoting resistance to existing drug therapies.
According to the authors, this is the first study of...
This webinar focuses on scientific, clinical, and patient-oriented strategies to help WGS's high clinical expectations.
Scientists at the University of Michigan’s Comprehensive Cancer Center have uncovered genetic markers in a rare type of breast cancer called phyllodes tumors by wielding a powerful new tool in the molecular diagnostics arsenal: Next-Gen sequencing.
This comprehensive investigation of gene alterations, a first for phyllodes tumors, was published in the journal Molecular Cancer Research today under the title, “Next-Gen...
Scientists at Geneseeq Technology share how to improve target capture for accurate clinical diagnostics by using optimized blocking oligonucleotides and stringent hybridization conditions.
The diverse array of mutations contributing to cancer complicates the selection of effective treatment regimens. There are only several hundred genes that can be targeted for cancer treatment, and the current trend is to selectively sequence these....
After many years of steady development in DNA sequencing, the scientific community is reaching an exciting threshold in understanding the genetic riddles behind cancerous tumors. Newly developing next-generation sequencing (NGS) techniques can rapidly analyze large quantities of DNA, offering a greatly enhanced understanding of the molecular complexity of disease. NGS promises to accelerate the understanding of cancer, helping to...
